These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33750261)

  • 1. Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections: A multicentric study.
    Sen S; Mishra C; Kannan NB; Ramasamy K; Rameshkumar G; Lalitha P
    Semin Ophthalmol; 2021 Aug; 36(5-6):413-422. PubMed ID: 33750261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.
    Wani VB; Al-Kandari J; Sabti K; Aljassar F; Qali H; Kumar N; Uboweja A; Al-Sabah K; Diab FA; Al-Rashidi S
    Middle East Afr J Ophthalmol; 2016; 23(1):64-70. PubMed ID: 26957841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results.
    Goldberg RA; Flynn HW; Miller D; Gonzalez S; Isom RF
    Ophthalmology; 2013 Jul; 120(7):1448-53. PubMed ID: 23453511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab.
    Karimi S; Fakhri N; Ansari I; Hassanpour K; Safi S
    Int Ophthalmol; 2022 Jun; 42(6):1827-1833. PubMed ID: 35079940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab.
    Goldberg RA; Flynn HW; Isom RF; Miller D; Gonzalez S
    Am J Ophthalmol; 2012 Feb; 153(2):204-208.e1. PubMed ID: 22264943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Pharmaceutical Compounding of Vascular Endothelial Growth Factor Inhibitors for Intravitreal Use Alter the Risk of Post-injection Endophthalmitis?
    Blom K; Bragadóttir R; Sivertsen MS; Moe MC; Jørstad ØK
    Ocul Immunol Inflamm; 2022 Apr; 30(3):713-716. PubMed ID: 33026900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone.
    Sheyman AT; Cohen BZ; Friedman AH; Ackert JM
    JAMA Ophthalmol; 2013 Jul; 131(7):864-9. PubMed ID: 23640384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Endophthalmitis after Intravitreal Injections: Risk Factors, Microbiology Profile, and Clinical Outcomes.
    Mishra C; Lalitha P; Rameshkumar G; Agrawal R; Balne PK; Iswarya M; Kannan NB; Ramasamy K
    Ocul Immunol Inflamm; 2018; 26(4):559-568. PubMed ID: 29437495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and Visual Outcomes of Acute Bacterial Endophthalmitis Following Intravitreal Injection of Contaminated Bevacizumab in a Single Day.
    Xu K; Mousa R; Loewenstein A; Barak A; Chin EK; Almeida DRP
    Ophthalmic Surg Lasers Imaging Retina; 2020 Jun; 51(6):346-352. PubMed ID: 32579693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
    Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Study of Microbiological Profile and Management Outcomes of Acute Endophthalmitis after Microincision Vitrectomy Surgery versus Intravitreal Injections.
    Kannan NB; Sen S; Mishra C; Lalitha P; Rameshkumar G; Rajan RP; Arumugam KK; Ramasamy K
    Ocul Immunol Inflamm; 2021 Jul; 29(5):838-844. PubMed ID: 31900009
    [No Abstract]   [Full Text] [Related]  

  • 19. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.
    Artunay O; Yuzbasioglu E; Rasier R; Sengül A; Bahcecioglu H
    Eye (Lond); 2009 Dec; 23(12):2187-93. PubMed ID: 19218994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.